Geriatric Oncology

Risks & contraindications

Where it comes from

Other

Highlighted claims

• In Japan, individuals aged 70 and over comprise the majority of cancer patients. — Feasibility of a mobile application-based geriatric assessment and communication support intervention for older adults with cancer: protocol for a pilot randomised controlled trial (MAPLE2 pilot)
• MAPLE2 eligibility requires patients to be aged 70 or older with solid cancer or lymphoma who are initiating or changing systemic anticancer therapy. — Feasibility of a mobile application-based geriatric assessment and communication support intervention for older adults with cancer: protocol for a pilot randomised controlled trial (MAPLE2 pilot)
• Older adults are systematically underrepresented in clinical trials, and treatment decisions are frequently extrapolated from studies of younger, selected populations. — Feasibility of a mobile application-based geriatric assessment and communication support intervention for older adults with cancer: protocol for a pilot randomised controlled trial (MAPLE2 pilot)
• Underrepresentation of older adults in trials creates a meaningful risk of both overtreatment and undertreatment in patients with ageing-related vulnerabilities. — Feasibility of a mobile application-based geriatric assessment and communication support intervention for older adults with cancer: protocol for a pilot randomised controlled trial (MAPLE2 pilot)
• Selection bias may arise in MAPLE2 because patients with cognitive impairment or limited digital literacy may be less likely to participate, potentially inflating feasibility estimates. — Feasibility of a mobile application-based geriatric assessment and communication support intervention for older adults with cancer: protocol for a pilot randomised controlled trial (MAPLE2 pilot)